LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Akebia Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

3.64 -2.67

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.59

Max

3.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

29M

6.1M

Verkäufe

11M

57M

EPS

0.025

Gewinnspanne

10.66

Angestellte

181

EBITDA

20M

14M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+90.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

345M

956M

Vorheriger Eröffnungskurs

6.31

Vorheriger Schlusskurs

3.64

Nachrichtenstimmung

By Acuity

49%

51%

154 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Juni 2025, 20:51 UTC

Ergebnisse

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. Juni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Juni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. Juni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. Juni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. Juni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Juni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. Juni 2025, 18:39 UTC

Market Talk
Ergebnisse

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. Juni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. Juni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. Juni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. Juni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. Juni 2025, 17:08 UTC

Ergebnisse

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. Juni 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. Juni 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. Juni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. Juni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

90.22% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  90.22%

Hoch 8 USD

Tief 6 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

154 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.